Alexandria Hammond
Stock Analyst at B of A Securities
(1.80)
# 3,182
Out of 4,944 analysts
16
Total ratings
54.55%
Success rate
-2.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $63 → $64 | $48.52 | +31.90% | 4 | May 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $556.34 | +106.71% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $25.08 | -0.30% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $26.87 | +48.86% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $82.31 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $659.91 | +51.54% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $174.25 | +9.04% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $120.00 | -8.33% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $47.60 | - | 1 | Nov 15, 2024 | |
| BIIB Biogen | Initiates: Peer Perform | n/a | $134.26 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $201.10 | +1.94% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $370.25 | -59.49% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $30 | $9.12 | +228.95% | 1 | Apr 22, 2024 |
Akero Therapeutics
May 27, 2025
Maintains: Buy
Price Target: $63 → $64
Current: $48.52
Upside: +31.90%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $556.34
Upside: +106.71%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $25.08
Upside: -0.30%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $26.87
Upside: +48.86%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $82.31
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $659.91
Upside: +51.54%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $174.25
Upside: +9.04%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $120.00
Upside: -8.33%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $47.60
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $134.26
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $201.10
Upside: +1.94%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $370.25
Upside: -59.49%
Apr 22, 2024
Assumes: Buy
Price Target: $30
Current: $9.12
Upside: +228.95%